A Domestic Dual-Antibody ADC Successfully Completes Outward BD

On August 29, Keyi (Zhejiang) Pharmaceutical Technology Co., Ltd. announced an exclusive licensing partnership with international biopharmaceutical company RADIANCE Biopharma. Keyi Pharma granted Radiance the overseas development, registration, and commercialization rights for KY-0301, the world’s first nano bispecific ADC drug.

According to the terms of the agreement, Keyi (Zhejiang) Pharmaceutical Technology Co., Ltd. will receive an upfront payment of $15 million, up to $150 million in research and development registration milestone payments, and up to $1 billion in commercialization milestone payments. Additionally, the company will also receive a tiered sales royalty based on the annual net sales in the licensed territory.

This isKeyi (Zhejiang) Pharmaceutical Technology Co., Ltd.'s Recent Second Pipeline Outward BD.

As early as July 22 this year, Keyi (Zhejiang) Pharmaceutical Technology Co., Ltd. announced an important strategic cooperation with the U.S.-based biopharmaceutical giant ERIGEN LLC. Both parties jointly signed an exclusive overseas licensing agreement for Keyi Pharma's self-developed innovative product KQ-2003, the world’s first parallel-enhanced dual-targeting CAR-T cell therapy targeting BCMA/CD19.